Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Conditions:   Lymphoplasmacytic Lymphoma;   Waldenstrom Macroglobulinemia Interventions:   Drug: Ibrutinib;   Biological: Rituximab;   Drug: Venetoclax Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials